Pfizer has entered into a licensing agreement with eFFECTOR Therapeutics to develop and commercialise translation regulation therapies for the treatment of cancer. The deal, which is worth up to US$507 M, combines eFFECTOR's development capabilities and know-how with Pfizer’s global commercial resources and validates the former’s approach to inhibiting eukaryotic initiation factor 4E (eIF4E). To date, eIF4E has proven to be a tough target for drug developers given the lack of clinical success.